Literature DB >> 12070414

[Induced interstitial pneumonitis: role of pegylated interferon alpha 2b].

Pierre Rocca1, Jérôme Dumortier, Philippe Tanière, Serge Duperret, Thierry Vial, Vincent Cottin, Bertrand Delafosse, Jean-Yves Scoazec, Olivier Boillot.   

Abstract

Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070414

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  4 in total

1.  Onset of bronchiolitis obliterans organizing pneumonia in a liver transplant recipient under peg-interferon and ribavirin treatment.

Authors:  Cristina Crespi; Silvia Gualandi; Fabio Piscaglia; Luigi Bolondi
Journal:  Intern Emerg Med       Date:  2008-02-07       Impact factor: 3.397

2.  Hepatitis C and pulmonary fibrosis: Hepatitis C and pulmonary fibrosis.

Authors:  Rasoul Aliannejad; Mostafa Ghanei
Journal:  Hepat Mon       Date:  2011-02       Impact factor: 0.660

3.  Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].

Authors:  Vanna Chiarion-Sileni; Paola Del Bianco; Antonella Romanini; Michele Guida; Adriano Paccagnella; Maurizio Dalla Palma; Emanuele Naglieri; Ruggero Ridolfi; Barbara Silvestri; Maria Michiara; Gian Luca De Salvo
Journal:  BMC Cancer       Date:  2006-02-27       Impact factor: 4.430

Review 4.  Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Authors:  Serena Slavenburg; Yvonne F Heijdra; Joost P H Drenth
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.